Introduction
Myeloproliferative neoplasms are clonal hematopoietic stem cell disorders characterized by the proliferation of one or more of the granulocytic, erythroid, megakaryocytic or mastocytic lineages. Th ese disorders form a heterogeneous group, with similar symptomatology and laboratory fi ndings, leading to a diffi cult diff erential diagnosis.
Th e fi rst classifi cation of these disorders was elaborated by William Dameshek in 1951: chronic myeloid leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET), primary myelofi brosis (PMF) and erythroleukemia were the original components of the myeloproliferative disorders' (MPD) group [1] . Further investigations refi ned this classifi cation, erythroleukemia was excluded and the remaining conditions were referred to as the classic MPDs. In 2001 the WHO classifi cation included the classic MPDs in the chronic myeloproliferative disease (CMD) category, along with chronic neutrophilic leukemia (CNL), chronic eosinophilic leukemia/ hypereosinophilic syndrome (CEL/ HES) and unclassifi able CMPD [1] .
Due to clarifi cation of the genetic background of these disorders and identifi cation of specifi c molecular markers (BCR-ABL oncogene, JAK2 mutation, KIT mutation) for myeloid neoplasms, the WHO elaborated a new classifi cation (2008) and included the classic MPDs, CNL, HES, CEL not otherwise categorized, unclassifi able CMPD and the newly-introduced mast cell disease (MCD) in the myeloproliferative neoplasms (MPN) category. Diagnostic criteria were updated to include the identifi cation of these genetic abnormalities, besides clinical signs, symptoms, blood count changes and bone marrow histology [2, 3] .
Th e diagnosis of CML is based on the detection of the Philadelphia chromosome -t(9;22)(q34;q11) -by conventional cytogenetic analysis and/or the resulting BCR-ABL fusion gene detected mainly by qualitative and/or quantitative reverse transcriptase polymerase chain reaction (RQ-PCR). Depending on the breakpoint's location on the BCR gene, three main variants of this fusion gene have been described, each of them encoding a diff erent molecular weight protein (the M-BCR-ABL gene the p190 protein, the m-BCR-ABL gene the p210 protein and the μBCR-ABL gene the p230 protein) with abnormal tyrosine kinase activity. Th e development of specifi c tyrosine Correspondence to: Zoltán Pávai E-mail: zpavai@yahoo.com kinase inhibitors (TKIs) -imatinib, nilotinib, dasatinib -completely changed the management of CML patients and became the gold standard therapy in chronic phase patients [4] .
Identifi cation of the Janus-2 kinase (JAK2) point mutations had a great impact on the diagnostic approach of PV, ET and PMF as those can be identifi ed in 95% of PV cases and in approximately 50% of ET and PMF patients. Th e most common JAK2 mutation is the V617F resulting from the substitution of valine for phenylalanine at the 617 position. Th e encoded mutant protein is able to activate its signaling pathways in the absence of any stimulus contributing to uncontrolled proliferation of the myeloid lineages [5] . Th e therapeutic perspective involves the application of specifi c JAK inhibitors, as several drugs (ruxolitinib, lestaurtinib, CYT387) have been developed after the discovery of JAK2 mutations and the clinical trials are being performed [3] .
Th e aim of this study was to investigate the role of molecular biology testing in the management of myeloproliferative neoplasms with emphasis on the M-BCR-ABL oncogene and JAK2 V617F mutation. For the identifi cation of M-BCR-ABL oncogene we performed RQ-PCR. One ml peripheral blood sample collected in EDTA tube was used for RNA extraction with QIAmp RNA Blood Mini Kit 50 (QIAGEN, Cat. No. 52304). RNA concentration and purity was measured using a NanoDrop spectrophotometer (ND-1000 Spectrophotometer V3.5). Th is was followed by DNA transcription with High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Cat. No. 4374966) according to supplier's instructions. To quantify the M-BCR-ABL expression level, we performed RQ-PCR analysis using an ABI 7500 Real Time PCR instrument (Applied Biosystem) with 25 μl fi nal volume: 5 μl cDNA and 20 μl TaqMan Universal PCR Master Mix (Applied Biosystem) using the primers and protocols recommended by the Europe Against Cancer Program [6] . We performed relative quantifi cation with the ABL gene as endogenous control [7] . All reactions were made in triplicate and we also utilized known positive and negative control samples.
Material and methods
For the detection of the JAK2 V617F mutation allelespecifi c polymerase chain reaction was used. DNA was extracted from 200 μl peripheral blood and subjected to PCR using GeneAmp PCR buff er, dNTP, reverse primer, forward primer and AmpliTaq Gold DNA Polymerase (Applied Biosystems) in a fi nal volume of 20 μl. After the amplifi cation, electrophoresis was performed on 1.5% agarose gel with pUC19 (SM 0223, Fermentas) as a DNA ladder [8] .
All the investigations were in accordance with the Declaration of Helsinki.
Th e statistical analysis was carried out with GraphPad Instat Version 3.06 software using Fischer's test and MannWhitney U test.
Results
Peripheral blood samples of 117 patients were tested during the mentioned period: in case of 44 patients we performed concomitant M-BCR-ABL and JAK2 V617F determination, 53 patients were tested only for M-BCR-ABL, and in case of 20 patients only JAK2 V617F analysis was performed. Th e results are shown in Table I .
Th e M-BCR-ABL positive group contains 16 patients evaluated at one occasion and 16 patients whose expression level was measured at regular intervals to monitor the therapeutic response. From the regularly monitored group two patients underwent hematopoietic stem cell transplantation (HSCT): one patient is currently in complete hematologic and molecular remission (undetectable M-BCR-ABL expression level) without any therapy after four years from the intervention, while the other presented early relapse and despite second-generation tyrosine kinase inhibitor therapy, he died at 13 months post-HSCT because of septic complications. Th e majority of the 14 medication treated and monitored patients receive fi rst generation TKI (imatinib) therapy, the expression level and clinical phase changes are shown in Table II .
Th e case of two CP phase patients should be mentioned: after decreasing M-BCR-ABL values, they presented increasing expression levels without signifi cant blood count changes, as shown in Table III . In case of patient number 2 we only selected two moments from the follow-up: diagnosis and signifi cant increase of M-BCR-ABL value. Between the two mentioned period we obtained very low (0.0055%) and even undetectable M-BCR-ABL expression level. Th e JAK2 V617F point mutation was identifi ed in case of 20 patients (15 patients from the concomitant group and 5 patients investigated only for JAK2 V617F ). Th e majority (8 patients) were diagnosed with PV, 4 patients with ET, 3 patients with PMF, 4 patients with unclassifi able CMPD and 1 patient with myelomonocytic leukemia.
In case of 42 patients we could not identify the presence of JAK2 V617F mutation. In almost half of them (20 patients) a diagnosis of any hematologic disease was excluded (the abnormal blood counts were interpreted in the context of autoimmune disorders, secondary to neoplasms or idiopathic). Th e remaining 22 patients maintained a hematologic diagnosis: the majority (17) were diagnosed with a form of CMPD (2 CML, 11 ET, 3 PV, 1 unclassifi able CMPD) based on bone marrow analysis and 5 patients were diagnosed with other hematologic diseases (Hodgkin, non-Hodgkin lymphoma, chronic lymphoid leukemia).
Th e comparison between clinical characteristics of PV and ET patients according to JAK2 mutational status is shown in Table IV .
Discussion
Th e understanding of the pathophysiology of myeloid neoplasms at the molecular level represented a huge breakthrough in the management of these disorders from the diagnostic approach to the elaboration of targeted therapies and follow-up.
CML represents a particular CMPD, it is a real success story; the discovery of molecular pathways lead to radical changes in the management of these patients: the diagnosis is based on the identifi cation of the Philadelphia chromosome and/or BCR-ABL fusion gene, as gold standard treatment targeted TKI therapy (imatinib 400 mg) is administered and cytogenetic and/or molecular analysis is recommended for regular follow-up [9] . In our study, we measured the M-BCR-ABL oncogene by RQ-PCR and monitored at regular intervals the changes of the expression levels after HSCT and under TKI therapy. Th e majority of chronic phase patients presented decreasing or stable values, while in case of accelerated phase and blast phase patients the M-BCR-ABL values increased or remained the same as we previously reported [10] . Th is confi rmed the reduced effi cacy of imatinib in these latter phases, which is concordant with international guidelines recommendations [11] .
In case of two chronic phase patients we observed increasing M-BCR-ABL values, and upon comparing this result with the blood count fi ndings, we noticed that hematologic parameters were not elevated, even when the transcript levels were much higher than previously. Consequently, monitoring patients by RQ-PCR testing, a very sensitive method, allows the timely identifi cation of resistant cases, therefore the therapeutic changes (dose increasing, switching to second generation TKI) can be accomplished in time.
Th e discovery of JAK2 mutations and their contribution in Ph-negative myeloproliferative neoplasms repre- sented an extremely important change in the management of these disorders. Numerous studies were carried out regarding the occurrence of mutations which reported diff erent occurrence ratios; nevertheless, it is widely accepted that the JAK2 V617F mutation can be identifi ed most frequently in PV (60-95%) cases and approximately in half of ET and PMF patients. In our study, despite the small number of positive cases, we can notice the same distribution: as we detected the JAK2 V617F mostly in PV patients (8 out of 20 positive cases), while other disorders -ET, PMFpresented the mutation less frequently (4/3 cases). Upon analyzing the fi nal diagnosis of JAK2 negative patients, we noted that there were signifi cantly more ET cases than PV cases. JAK2 V617F is not specifi c for any single MPN, but because of the high incidence rate in PV it became the preferred initial testing according to WHO criteria, as it is an useful resource to exclude secondary causes of PV [12] . However, JAK2 V617F negative PVs were described, in such cases further investigations are needed: commonly other than V617F mutations of the JAK2 gene are involved, especially those aff ecting exon 12 [13, 14] . Unfortunately, as the specifi city of JAK mutations in ET and PMF is reduced, we can not exclude these disorders in case of absence of JAK2 V617F .
Comparing the blood count parameters according to the presence or absence of JAK2 V617F mutation in case of PV, we found signifi cant diff erences in the hemoglobin and hematocrit values, those carrying the mutations presenting higher values, and JAK2 V617F positive ET patient's platelet counts were signifi cantly greater than those lacking the mutation; the other variables showed statistically not signifi cant diff erences. However, due to the restricted number of investigated patients and the diversity of reported data we should interpret this result cautiously. A great number of studies investigated the diff erences between clinical phenotype and blood count parameters according to mutational status with large variation of the results. A German study could not fi nd any correlation between the presence of mutation and clinical parameters of PV and ET patients, however Chinese and Korean scientists reported signifi cant correlation between the presence of mutation and blood count parameters, but the results are divergent: while in one study JAK2 V617F positive ET patients showed higher neutrophil and leukocyte counts, the other study found that ET patients carrying the mutations were older, with higher neutrophil counts, with greater risk for myelofi brosis and thrombotic events [15] [16] [17] . Th e clinical picture of MPDs is very diverse and there is no blood count parameter available that could predict the presence or absence of mutations and further research is needed to estabilish the characteristics of mutation carriers.
An interesting aspect is the role of JAK2 mutation in other myeloid malignancies, as it was described in acute myeloid leukemia and myeloproliferative/myelodisplastic syndromes (chronic myelomonocyitc leukemia-CMML, atypical Ph-CML) as well. A study conducted on 374 patients with hematologic neoplasms identifi ed the presence of JAK2 V617F point mutation in 3 out of 16 cases of atypical CML and in 7 of 53 patients with CMML [18] . Regarding the presence of JAK2 V617F in myeloid malignancies other than PV, ET and PMF we have one CMML patient in our database with splenomegaly, anemia and high neutrophil count at presentation. Th is observation partially matches the results of a study performed on 78 CMML patients, which identifi ed this mutation in 8 cases, all patients presenting splenomegaly and signifi cantly higher hemoglobin levels and neutrophil counts than those lacking this genetic aberration [19] .
We did not fi nd any patient with concomitant occurrence of JAK2 V617F and BCR-ABL, but lately such cases were reported. In these case presentations there is no specifi c pattern: some cases presented both genetic abnormalities at the moment of diagnosis, others during the course of the disease. Th e fi rst diagnosis is also variable: it was either CML, either PV, but in the majority of cases BCR-ABL subclones were the dominant ones, JAK2 V617F subclones becoming manifest only after the suppression of BCR-ABL with targeted TKI therapy. In such cases the patients had abnormal blood counts (leukocytosis, trombocytosis), rising the suspicion of TKI therapy failure or resistance, but molecular testing clarifi es the situation [20] [21] [22] .
Compared to the 2001 WHO criteria, one of the innovations of the 2008 system was the classifi cation based on the presence of a genetic marker, but the classifi cation does not refer to situations with more than one genetic abnormality, therefore this aspect needs to be clarifi ed.
Conclusions
As more and more molecular pathways are understood, genetic investigations acquire an important role in the management of myeloproliferative neoplasms.
In case of CML patients, the presence of the BCR-ABL oncogene confi rms the diagnosis, and monitoring the expression levels by RQ-PCR, a highly sensitive method, allows early identifi cation of resistant cases, enabling timely therapeutic changes.
Th e detection of the JAK2 V617F point mutation is an important part of the diagnosis of myeloproliferative neoplasms as it is present in most of the PV cases, and almost half of the ET and PMF patients, helping the physician to exclude secondary causes of elevated blood count parameters. Th ere is a perspective of introducing targeted JAK2 inhibitor therapy for mutation carrier patients, as undergoing clinical trials show promising results.
